Kevin Rakin Biography and Net Worth

Director of Elutia

Kevin Rakin has served as our chairman and a member of our board of directors since November 2015. Mr. Rakin is Co-founder of HighCape Partners, an investment fund and affiliate of Elutia, and has been a general partner in HighCape Partners since 2013. Additionally, Mr. Rakin serves as Chief Executive Officer of HighCape Capital Acquisition Corp., a publicly traded affiliate of HighCape Partners, since June 2020. Since 2014, Mr. Rakin has also been a member of the board of directors of Oramed Pharmaceuticals Inc., a publicly traded pharmaceutical company, where Mr. Rakin serves on the Audit and Compensation Committee. Mr. Rakin has also served, and continues to serve, on the board of directors of several private companies, including Convexity Scientific Inc. since 2017, Nyxoah S.A., a publicly traded medical device company, since 2016 and Cybrexa, Inc. since 2016. Prior to and during the last five years, Mr. Rakin has served on the board of directors of various private and publicly traded biomedical and pharmaceutical companies, including Histogenics Corp., where Mr. Rakin served on the Audit and Compensation Committee, TELA Bio, Inc., Cheetah Medical, Inc. and Collagen Matrix, Inc. Mr. Rakin holds an M.B.A. from Columbia University and B.Com and B.Com (Hons) degrees from the University of Cape Town, South Africa.

What is Kevin Rakin's net worth?: The estimated net worth of Kevin Rakin is at least $162.78 thousand as of January 30th, 2026. Rakin owns 196,120 shares of Elutia stock worth more than $162,780 as of September 28th. This net worth evaluation does not reflect any other investments that Rakin may own. Learn More about Kevin Rakin's net worth.
How do I contact Kevin Rakin?: The corporate mailing address for Rakin and other Elutia executives is 12510 Prosperity Drive, Suite 370, Silver Spring, MD, 20904. Elutia can also be reached via phone at (240) 247-1143 and via email at [email protected]. Learn More on Kevin Rakin's contact information.
Has Kevin Rakin been buying or selling shares of Elutia?: Kevin Rakin has not been actively trading shares of Elutia during the last quarter. Most recently, on Friday, January 30th, Kevin Rakin bought 70,000 shares of Elutia stock. The stock was acquired at an average cost of $1.06 per share, with a total value of $74,200.00. Following the completion of the transaction, the director now directly owns 196,120 shares of the company's stock, valued at $207,887.20. Learn More on Kevin Rakin's trading history.
Who are Elutia's active insiders?: Elutia's insider roster includes Thomas Englese (Insider), Matthew Ferguson (CFO), Ronald Lloyd (CEO), and Kevin Rakin (Director). Learn More on Elutia's active insiders.
Are insiders buying or selling shares of Elutia?: In the last year, Elutia insiders bought shares 13 times. They purchased a total of 299,500 shares worth more than $220,810.00. The most recent insider tranaction occured on January, 30th when Director Guido J Neels bought 20,000 shares worth more than $20,800.00. Insiders at Elutia own 17.8% of the company. Learn More about insider trades at Elutia.
Information on this page was last updated on 1/30/2026.

Kevin Rakin Insider Trading History at Elutia

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/30/2026	Buy	70,000	$1.06	$74,200.00	196,120
12/17/2025	Buy	50,000	$0.52	$26,000.00	322,419

Kevin Rakin Buying and Selling Activity at Elutia

Elutia Company Overview

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Today's Range

Now: $0.83

$0.83

50 Day Range

MA: $0.87

$0.79

$1.01

2 Week Range

Now: $0.83

$0.50

$1.39

Volume

823 shs

Average Volume

135,263 shs

Market Capitalization

$36.76 million

P/E Ratio

0.87

Dividend Yield

N/A

Beta

0.88